Drug intelligence / Profile preview

RO7445482 + RO7049389 + nucleos(t)ide

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral

Overview

RO7445482 + RO7049389 + nucleos(t)ide is an investigational **triple combination antiviral regimen for chronic hepatitis B virus (HBV) infection**. It combines RO7445482, a short interfering RNA (siRNA) designed to silence viral transcripts; RO7049389, a core protein allosteric modulator (CpAM) that disrupts HBV nucleocapsid assembly; and a background nucleos(t)ide analogue (NUC), which is a class of approved oral antiviral agents that inhibit HBV DNA polymerase and viral replication. The combination approach targets multiple steps in the HBV lifecycle to maximize antiviral efficacy and potentially achieve functional cure. Clinical trials have evaluated the safety and efficacy of this combination in adults with chronic HBV infection[1][2][3][5].

Other names: siRNA (RO7445482) + CpAM (RO7049389) + NUC

Targets

HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on RO7445482 + RO7049389 + nucleos(t)ide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7445482 + RO7049389 + nucleos(t)ide.

Explore the full profile